2022
DOI: 10.1002/alz.060511
|View full text |Cite
|
Sign up to set email alerts
|

Donepezil prevents cognitive impairment and gut epithelial disruption in doxorubicin‐treated rats

Abstract: BackgroundDonepezil (DPZ) is an acetylcholinesterase inhibitor used to improve cognitive function. We reported that it prevented doxorubicin (Dox)‐induced chemobrain. Gut epithelial disruption, gut dysbiosis and impaired essential microbial metabolites, such as short chain fatty acids (SCFAs), have found following Dox therapy. However, the impact of DPZ to prevent gut epithelial disruption and gut dysbiosis as well as disturbance of circulating SCFAs due to Dox‐induced chemobrain have been never investigated.M… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles